For the second randomization in CRVO patients , there was no significant difference from week 24 BCVA in the ranibizumab plus laser versus the ranibizumab only groups at week 48 ( -3.3 vs. 0.0 letters ) , week 96 ( +0.69 vs. -1.6 letters ) , or week 144 ( +0.4 vs. -6.7 letters ) , and a significant increase from week 24 mean CST at week 48 ( +94.7 vs. +15.2 m ; P = 0.05 ) but not weeks 96 or 144 .